June 2019 - Volume 3 - Issue S1 - Contributor Index

Author:
Kaastrup, K.
Author:
Kaaz, K.
Author:
Kabanova, A.
Author:
Kabat, B.F.
Author:
Kabelitz, D.

S129 TP53 SOMATIC MUTATIONS AS PRE-LEUKEMIC EVENTS IN ACUTE LYMPHOBLASTIC LEUKEMIA

Chitadze, G.; Stengel, A.; John-Klaua, C.; More

HemaSphere. 3(S1):16-17, June 2019.

Author:
Kabir, S.

S831 CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) INHIBITOR, REDUCES PRO-INFLAMMATORY CYTOKINES, BONE MARROW FIBROSIS AND THE NUMBER OF TRANSFUSIONS IN MYELOFIBROSIS PATIENTS

Hoffman, R.; Mascarenhas, J.; Kremyanskaya, M.; More

HemaSphere. 3(S1):369, June 2019.

Author:
Kacem, K.
Author:
Kacem, S.

PF524 EVALUATION OF SERINE BIOSYNTHESIS PATHWAY AS A POTENTIAL THERAPEUTIC TARGET IN BURKITT LYMPHOMA

Noyszewska-Kania, M.; Bialopiotrowicz, E.; Cybulska, M.; More

HemaSphere. 3(S1):214-215, June 2019.

Author:
Kaczynski, H.

PF558 THE ANTI-BCMA ANTIBODY-DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE-MEDIATED ANTI-TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST POTENTIATES IN VIVO ACTIVITY

Montes De Oca, R.; Bhattacharya, S.; Vitali, N.; More

HemaSphere. 3(S1):231, June 2019.

Author:
Kadel, S.-K.
Author:
Kader, A.
Author:
Kadia, T.

PF205 RNA BASED IMMUNE SIGNATURES MAY PREDICT RESPONSES TO PD-1 INHIBITION AND AZACITIDINE TREATMENT IN ACUTE MYELOID LEUKEMIA (AML): A SUBSET ANALYSIS OF A PHASE 2 STUDY

Abbas, H.; Alfayez, M.; Wang, F.; More

HemaSphere. 3(S1):54-55, June 2019.

PF291 A PHASE 1B/2 CLINICAL STUDY OF TARGETED IDH1 INHIBITION WITH IVOSIDENIB, IN COMBINATION WITH THE BCL-2 INHIBITOR VENETOCLAX, FOR PATIENTS WITH IDH1-MUTATED (MIDH1) MYELOID MALIGNANCIES

Dinardo, C.; Takahashi, K.; Kadia, T.; More

HemaSphere. 3(S1):97, June 2019.

PF673 PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML)

Bose, P.; Verstovsek, S.; Naqvi, K.; More

HemaSphere. 3(S1):289-290, June 2019.

S829 SOTATERCEPT (ACE-011) IN SUBJECTS WITH MPN-ASSOCIATED MYELOFIBROSIS AND ANEMIA

Bose, P.; Pemmaraju, N.; Daver, N.; More

HemaSphere. 3(S1):367-368, June 2019.

PS1064 EXPLORATORY ANALYSIS OF OUTCOMES WITH SEQUENTIAL FLT3-INHIBITOR (FLT3I) BASED THERAPIES IN RELAPSED FLT3-MUTATED AML PATIENTS (PTS)

Alfayez, M.; Kantarjian, H.; Ravandi, F.; More

HemaSphere. 3(S1):481-482, June 2019.

S1614 CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA

Angenendt, L.; Röllig, C.; Montesinos, P.; More

HemaSphere. 3(S1):744-745, June 2019.

PB1722 IMPACT OF CD33 AND ABCB1 SINGLE NUCLEOTIDE POLYMORPHISMS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH DECITABINE PLUS GEMTUZUMAB OZOGAMICIN

Short, N.; Richard-Carpentier, G.; Kanagal-Shamanna, R.; More

HemaSphere. 3(S1):791-792, June 2019.

Author:
Kadia, T. M.

S1615 SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY.

Daver, N.; Alfayez, M.; Garcia-Manero, G.; More

HemaSphere. 3(S1):745, June 2019.

Author:
Kadish, K.

PF383 PROGNOSTIC TESTING AND TREATMENT APPROACHES BASED ON REAL-WORLD CLINICAL EXPERIENCE FROM AN INTERIM ANALYSIS OF THE INFORMCLL REGISTRY OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

Mato, A.R.; Barrientos, J.C.; Brander, D.; More

HemaSphere. 3(S1):143-144, June 2019.

Author:
Kadnikova, T.

PB1996 PROGNOSTICATION OF HODGKIN'S LYMPHOMA BY IPET AND IPS: UPDATE DATA OF 8 HEMATOLOGICAL UKRAINIAN CENTERS.

Novosad, O.; Skrypets, T.; Pastushenko, I.; More

HemaSphere. 3(S1):903-904, June 2019.

Author:
Kafantari, A.
Author:
Kafantari, K.
Author:
Kaguelidou, F.
Author:
Kahl, B.

S102 POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) AND LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): INTERIM ANALYSIS OF A PHASE IB/II TRIAL

Abrisqueta, P.; Kahl, B.; Banerjee, L.; More

HemaSphere. 3(S1):2-3, June 2019.

Author:
Kaiser, K.

PF734 PATIENT PREFERENCES FOR THE TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS OF A PATIENT SURVEY OF RAVULIZUMAB (ALXN1210) AND ECULIZUMAB

Peipert, J.D.; Kulasekararaj, A.; Gaya, A.; More

HemaSphere. 3(S1):321, June 2019.

Author:
Kaiser, M.

S823 RANDOMIZED, OPEN-LABEL, NON-INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA

Mateos, M.-V.; Nahi, H.; Legiec, W.; More

HemaSphere. 3(S1):364, June 2019.

S873 EFFICACY OF QUADRUPLET KCRD (CARFILZOMIB, CYCLOPHOSPHAMIDE, LENALIDOMIDE AND DEXAMETHASONE) INDUCTION FOR NEWLY DIAGNOSED MYELOMA PATIENTS: ANALYSIS OF THE MYELOMA XI STUDY BY MOLECULAR RISK

Pawlyn, C.; Kaiser, M.; Davies, F.; More

HemaSphere. 3(S1):391, June 2019.

Author:
Kaivers, J.

S840 IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA – A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP

Pleyer, L.; Leisch, M.; Kouraklis, A.; More

HemaSphere. 3(S1):374-375, June 2019.

Author:
Kaizer, H.

S834 PEGCRISANTASPASE AND VENETOCLAX COMBINATION IS HIGHLY EFFECTIVE AGAINST ACUTE MYELOID LEUKEMIA (AML), MECHANISTICALLY DRIVEN SYNERGISM BETWEEN GLUTAMINE DEPLETION AND BCL-2 INHIBITION

Emadi, A.; Gartenhaus, R.; Bhandary, B.; More

HemaSphere. 3(S1):370-371, June 2019.

Author:
Kakadiya, P.M.
Author:
Kakinoki, Y.

PF184 EFFICACY OF CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO ACHIEVED COMPLETE REMISSION BY FIRST COURSE OF REMISSION INDUCTION THERAPY

Shigematsu, A.; Ota, S.; Kobayashi, R.; More

HemaSphere. 3(S1):44, June 2019.

PF407 TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4

Murai, K.; Kimura, S.; Imagawa, J.; More

HemaSphere. 3(S1):155-156, June 2019.

PS1263 CONSOLIDATION THERAPY USING 90Y-IBRITUMOMAB TIUXETAN AFTER BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA; A MULTICENTER, PHASE II STUDY (BRIZ2012)

Tsujimura, H.; Miura, K.; Kanno, M.; More

HemaSphere. 3(S1):578, June 2019.

Author:
Kakkar, N.
Author:
Kako, S.

PS1277 EVALUATION OF THE IMMUNITY TO MEASLES, MUMPS AND RUBELLA IN ADULT PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Kawamura, K.; Nakasone, H.; Wada, H.; More

HemaSphere. 3(S1):584-585, June 2019.

S1639 SAFETY AND EFFICACY OF LIVE ATTENUATED VARICELLA VACCINE FOR PREVENTING VARICELLA ZOSTER VIRUS DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE SINGLE-CENTER STUDY

Kawamura, K.; Nakasone, H.; Akahoshi, Y.; More

HemaSphere. 3(S1):758, June 2019.

Author:
Kakuta, Y.
Author:
Kalabus, J.

S825 EVALUATION OF AMG 420, AN ANTI-BCMA BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST-IN-HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY

Topp, M.; Duell, J.; Zugmaier, G.; More

HemaSphere. 3(S1):365, June 2019.

Author:
Kalakonda, N.

PF296 UPDATE OF THE SINGLE-ARM PHASE II L-MIND STUDY OF MOR208 PLUS LENALIDOMIDE IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: HIGH OVERALL RESPONSE RATES IN PATIENT SUBGROUPS WITH POOR PROGNOSIS

Duell, J.; Maddocks, K.; González Barca, E.; More

HemaSphere. 3(S1):100, June 2019.

PF483 EFFICACY WAS IMPROVED WITH LENALIDOMIDE/RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH FOLLICULAR LYMPHOMA IRRESPECTIVE OF POD24 STATUS IN THE PHASE III AUGMENT STUDY

Leonard, J.P.; Trneny, M.; Izutsu, K.; More

HemaSphere. 3(S1):193-194, June 2019.

PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT)

Gribben, J.; Trneny, M.; Izutsu, K.; More

HemaSphere. 3(S1):571-572, June 2019.

PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

Thieblemont, C.; Leonard, J.P.; Trneny, M.; More

HemaSphere. 3(S1):577-578, June 2019.

Author:
Kalff, A.

PF604 THE AUSTRALASIAN LEUKAEMIA AND LYMPHOMA (ALLG) GROUP MM17 TRIAL: RESPONSE ADAPTIVE SALVAGE WITH CARFILZOMIB-THALIDOMIDE-DEXAMETHASONE FOR MULTIPLE MYELOMA PATIENTS FAILING FRONT-LINE BORTEZOMIB

Spencer, A.; Quach, H.; Horvath, N.; More

HemaSphere. 3(S1):255-256, June 2019.

PF693 PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN THE ELRDELRY AND YOUNGER ADULTS: REAL-WORLD COMPARATIVE RETROSPECTIVE STUDY FROM THE ITP REGISTRY OF THE HELLENIC SOCIETY OF HEMATOLOGY

Pontikoglou, C.; Kaliafentaki, V.; Stavroulaki, E.; More

HemaSphere. 3(S1):301, June 2019.

Author:
Kalina, T.

PF176 MONOCYTIC SWITCH AND DISCREPANCY BETWEEN FLOW CYTOMETRIC AND MOLECULAR MINIMAL RESIDUAL DISEASE ARE FREQUENT IN DUX4 REARRANGED AND PAX5-P80R MUTATED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

Novakova, M.; Vakrmanova, B.; Slamova, L.; More

HemaSphere. 3(S1):40-41, June 2019.

Author:
Kállay, K.

PF677 DNA HYPERMETHYLATION EMERGES AS THE STRONGEST PREDICTOR FOR POOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)

Niemeyer, C.M.; Flotho, C.; Lipka, D.B.; More

HemaSphere. 3(S1):292, June 2019.

Author:
Kallel, C.
Author:
Kallel, F.
Author:
Kalpadakis, C.

PF297 COMPARISON OF RITUXIMAB DOSE-ADJUSTED EPOCH (R-DA-EPOCH) WITH RITUXIMAB-CHOP (R-CHOP) CHEMOTHERAPY IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL)

Vassilakopoulos, T.; Mellios, Z.; Verigou, E.; More

HemaSphere. 3(S1):100-101, June 2019.

PS1089 PET-SCAN FOR RESPONSE ASSESSEMENT AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): CLINICAL AND PROGNOSTIC SIGNIFICANCE

Vassilakopoulos, T.; Chatzidimitriou, C.; Mellios, Z.; More

HemaSphere. 3(S1):494, June 2019.

PS1258 CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): CLINICAL SIGNIFICANCE OF ABSOLUTE CLONAL B CELL COUNTS

Kalpadakis, C.; Pangalis, G.; Konstantinou, I.; More

HemaSphere. 3(S1):575, June 2019.

PB1881 EVALUATION OF THE QUANTITATIVE CHARACTERISTICS OF MYELOID DERIVED SUPPRESSOR CELLS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND ASSOCIATED HYPOGAMMAGLOBULINEMIA

Zavisanou, K.; Bizymi, N.; Ioneskou, K.; More

HemaSphere. 3(S1):857, June 2019.

Author:
Kalter, D.
Author:
Kalwak, K.
Author:
Kalyva, S.
Author:
Kamachi, K.
Author:
Kamal, T.
Author:
Kamalakar, R.
Author:
Kamara, I.
Author:
Kamata, K.
Author:
Kambhampati, S.

S878 THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 IS ACTIVE AND WELL TOLERATED ALONE OR IN COMBINATION WITH AZACITIDINE IN AML AND MDS PATIENTS: INITIAL PHASE 1B RESULTS

Sallman, D.; Donnellan, W.; Asch, A.; More

HemaSphere. 3(S1):394, June 2019.

Author:
Kameda, K.

PS1277 EVALUATION OF THE IMMUNITY TO MEASLES, MUMPS AND RUBELLA IN ADULT PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Kawamura, K.; Nakasone, H.; Wada, H.; More

HemaSphere. 3(S1):584-585, June 2019.

S1639 SAFETY AND EFFICACY OF LIVE ATTENUATED VARICELLA VACCINE FOR PREVENTING VARICELLA ZOSTER VIRUS DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PROSPECTIVE SINGLE-CENTER STUDY

Kawamura, K.; Nakasone, H.; Akahoshi, Y.; More

HemaSphere. 3(S1):758, June 2019.

Author:
Kamel-Reid, S.

PF410 DOUBLING TIME AFTER FIRST ATTEMPT OF IMATINIB DISCONTINUATION IS HELPFUL TO IDENTIFY THE BEST CANDIDATE FOR THE SECOND ATTEMPT FOR TREATMENT-FREE REMISSION WITH DASATINIB: CANADIAN TRAD TRIAL

Kim, D.; Busque, L.; Forrest, D.; More

HemaSphere. 3(S1):157-158, June 2019.

PS1027 ASSESSMENT OF MOLECULAR MRD KINETICS BY ERROR-CORRECTED NEXT-GENERATION SEQUENCING PROVIDES INDEPENDENT PROGNOSTIC INFORMATION IN ADULT AML PATIENTS

Murphy, T.; Zou, J.; Wang, T.T.; More

HemaSphere. 3(S1):463, June 2019.

Author:
Kamelskikh, D.

PF755 PD-1 PATHWAY IS A KEY IMMUNOSUPPRESSIVE MECHANISM IN PATIENTS AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH TCR AB–DEPLETION

Popova, N.; Drokov, M.; Davydova, Y.; More

HemaSphere. 3(S1):331-332, June 2019.